Resolution of ear discharge ‐ measured at 1 to 2 weeks · people (of any age) with CSOM
It is very uncertain whether quinolones changes resolution of ear discharge ‐ measured at 1 to 2 weeks compared with aminoglycosides (very low certainty).
1 finding from 1 review
Resolution of ear discharge ‐ measured after 4 weeks · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ear pain (otalgia) or discomfort or local irritation · people (of any age) with CSOM
1 finding from 1 review
Hearing · people (of any age) with CSOM
1 finding from 1 review
Serious complications · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Suspected ototoxicity · people (of any age) with CSOM
1 finding from 1 review
Resolution of ear discharge (1 to 2 weeks) Quinolones · chronic suppurative otitis media
Topical antibiotics (quinolones) probably leads to higher resolution of ear discharge (1 to 2 weeks) Quinolones compared with boric acid (moderate certainty).
1 finding from 1 review
Exacerbations · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Response rate ‐ treatment failure · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
Fluoroquinolones may leads to lower response rate ‐ treatment failure compared with amoxicillin (low certainty).
1 finding from 1 review
Response rate ‐ microbiological response · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
Fluoroquinolones may leads to higher response rate ‐ microbiological response compared with amoxicillin (low certainty).
1 finding from 1 review
Response rate ‐ improvement in sputum purulence (excellent) · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
It is very uncertain whether fluoroquinolones changes response rate ‐ improvement in sputum purulence (excellent) compared with amoxicillin (very low certainty).
1 finding from 1 review
Deaths · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Quality of life · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events clinical criteria · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes other adverse events clinical criteria compared with beta‐lactams (very low certainty).
1 finding from 1 review
Diarrhoea · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes diarrhoea on compared with macrolides (very low certainty).
1 finding from 1 review
Relapse ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events clinical criteria · patients with Shigella dysentery
It is very uncertain whether fluoroquinolones changes other adverse events clinical criteria compared with macrolides (very low certainty).
1 finding from 1 review